Amwell (NYSE: AMWL) reported Q4 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $72.8 million versus the consensus estimate of $69.07 million.

GUIDANCE:

Amwell sees FY2022 revenue of $275-285 million, versus the consensus of $312 million.

For earnings history and earnings-related data on Amwell (AMWL) click here.